Global

A U.S. House committee has launched national security investigations into Merck, AbbVie, Eli Lilly, Pfizer, and Bristol Myers Squibb over their clinical trial operations in China, seeking answers by July 17 on data protection, military hospital ties, and trial sites in Xinjiang.

Once a niche pilot, direct-to-patient drug distribution is now a defining strategic priority, with manufacturers building the right infrastructure standing to capture margin, data, and patient relationships that used to belong to intermediaries.

In today's Pharmaceutical Executive Daily, Bruce Liu examines China's latest policy guidance establishing premium pricing and priority reimbursement access for truly innovative drugs, Parabilis Medicines surges more than 45 percent on its first day of trading on Nasdaq, and Pharmaceutical Executive speaks with Eli Lilly's Sarah O'Keeffe, Group Vice President of Product Research and Development, on how the company's $4.5 billion Medicine Foundry is designed to transform the discovery-to-production handoff and accelerate speed to patient.

China’s latest policy guidance sets new expectations for the pricing and reimbursement of novel drugs, and highlights the growing role of real-world evidence.

Over the past decade, PRCCI has helped bring more than 300 clinical trial opportunities to Puerto Rico, supported over 90 clinical research contracts, and collaborated with more than 116 physicians and investigators across the Island.

With more than $43 billion committed in five months, the pharma industry isn't just licensing from China, it's restructuring where global drug discovery begins.

WHO identifies experimental therapies from Mapp Biopharmaceutical, Regeneron, and Gilead as leading candidates for the Bundibugyo strain of Ebola virus disease, as the agency pushes for urgent clinical trials amid a growing outbreak.

Rigel Pharmaceuticals has licensed Veppanu, positioning the company to expand into protein degradation-based oncology treatments for ESR1-mutated metastatic breast cancer.

GSK partners with Sino Biopharmaceutical’s CTTQ unit to support the launch of hepatitis B candidate Bepirovirsen in mainland China, leveraging a commercial network spanning more than 5,000 medical centers.

Angelini Pharma acquires Catalyst Pharmaceuticals in a $4.1 billion deal, expanding into the U.S. rare disease market and adding a portfolio of approved neuromuscular and neurological therapies.

Charlie Lyon, VP of manufacturing, procurement, and logistics at the API Innovation Center, discusses the complicated web of global manufacturing.

Innomar’s VP of commercial strategy and innovation discusses the shifting global landscape and building relationships with pharma manufacturers.

Kaida Biopharma’s chair and acting CEO discusses how President Trump’s MFN policies and other regulatory actions are impacting pharma’s ability to invest in new treatments and adjusting international launch strategies.

The ongoing volatility in the Middle East and disruption risks tied to the Strait of Hormuz are exposing a broader but often underappreciated vulnerability in global pharmaceuticals.

Ireland has built a track record of regulatory excellence that few regions have matched.

China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy.

The U.S. government’s contract with Shionogi highlights renewed public-private investment in antimicrobial resistance and biodefense, aiming to strengthen domestic manufacturing and expand the role of novel antibiotics against high-priority threats.

Dan Bell, chief strategy officer at Marken, discusses how biopharma companies and logistics teams are responding to the dual disruptors to global supply chain operations.

Members of PacBio and iHope discuss collaboration and the global state of genomic testing.

Conflict in the Middle East is forcing pharmaceutical companies to reroute temperature-sensitive medicines through alternative corridors.

Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.

In this video episode, Pratap Khedkar, PhD, CEO of ZS, joins the Pharm Exec Podcast to discuss three distinct industry trends and strategy shifts converging at the moment amid the backdrop of US-driven global policy change.

Following the decisions=, the European Commission decided to close a long-running antitrust investigation

Most medical digital pilots are designed for success in controlled conditions.

The shifting landscape amid China's biotech rises presents both opportunities and geopolitical challenges for growth strategies.